Intravenous ketamine therapy in a patient with a treatment-resistant major depression

Swiss Medical Weekly

Volumn 137, Issue 15-16, 2007, Pages 234-236

  Liebrenz, Michael ^a   Borgeat, Alain ^b   Leisinger, Ria ^a   Stohler, Rudolf ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Ketamine; N methyl d aspartate receptor antagonist; Treatment resistant major depression

Indexed keywords

BENZODIAZEPINE; KETAMINE;

ADULT; ALCOHOLISM; ARTICLE; CASE REPORT; CLINICAL TRIAL; COMORBIDITY; DRUG DEPENDENCE; HUMAN; INTERVIEW; MAJOR DEPRESSION; MALE; RATING SCALE; SUBSTANCE ABUSE; TREATMENT RESPONSE;

EID: 34249314353     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-71.
2. Check E. Depression: Comfortably numb. Nature. 2006;443:629-31.
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-4.
4. Zarate CA Jr, Singh JB, Carlson PJ, Brusche NE, Ameli R, Luckenbaugh DA, et al. A randomised trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-64.
5. King PH, Shin C, Mannsbach HH, Chen LS, McNamara JO. Microinjection of a benzodiazepine into substantia nigra elevates kindled seizure threshold. Brain Res. 1987;423:261-8.
6. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
7. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7:151-69.